Insulin stimulates hepatic de novo lipogenesis and suppresses gluconeogenesis in physiological conditions while both pathways are increased in obesity-associated pathological conditions6, where it is an urgent clinical need to identify target molecule(s) to properly suppress both pathways as well as other pathology-associated pathways. The gene discussed is INS; the disease is obesity disorder.